Clinical trials: Neck Cancer
Ovarian Cancer, Endometrial Cancer
Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers
Rationale: The administration of prophylactic G-CSF may reduce the toxicity of a weekly paclitaxel/carboplatin regimen in gynaecological cancers.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Uterine Cervical Cancer
- Trial name
- NCT01523678
- Testing
- Filgrastim, Paclitaxel, Carboplatin
- Where
- 17 sites in Belgium
- Volunteers
- 108 people
- Sponsor
- Belgian Gynaecological Oncology Group
Esophagus Cancer, Esophageal Cancer
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Rates of local disease control in patients with locally advanced esophageal cancer who are not candidates for surgical resection are suboptimal.
- Conditions
- Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
- Trial name
- NCT04046575
- Testing
- Intensity Modulated Radiation Therapy, Carboplatin, MD Anderson Symptom Inventory (MDASI)-Plus module
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Washington University School of Medicine
Thyroid Carcinoma, Dyslipidemias
Lipid Metabolic Status in Thyroid Carcinoma
The continuous increase of the incidence of the thyroid cancer in the last years has taken this neoplasia among the first 4 frequent cancers in the cancer registry of the Institute of Oncology "Prof.Ion Chiricuţă" from…
- Conditions
- Thyroid Carcinoma, Dyslipidemias, Risk Reduction Behavior, Hormone Replacement
- Trial name
- LITCA (NCT01487057)
- Where
- Romania
- Volunteers
- 52 people
- Sponsor
- Prof. Dr. I. Chiricuta Institute of Oncology
Colorectal Cancer, Bladder Cancer
Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)
This is a proof-of-concept pilot randomized clinical trial to test the feasibility of the innovative Patient-Reported Outcomes-Informed Symptom Management System (PRISMS) to enhance personalized supportive care for cancer…
- Conditions
- Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- PRISMS (NCT04492007)
- Testing
- Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
This phase II trial studies how well durvalumab and epacadostat work in treating patients with Epstein-Barr virus positive nasopharyngeal cancer that cannot be removed by surgery (unresectable), has come back (recurrent), or has…
- Conditions
- Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma
- Trial name
- NCT04231864
- Testing
- Durvalumab, Epacadostat
- Sponsor
- Alain Algazi
Non Small Cell Lung Cancer, Colorectal Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT05395052
- Testing
- FT536, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fate Therapeutics
Pancreatic Cancer, Esophageal Cancer
HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery
A one-group prospective cohort study design with measures collected pre- and post-intervention. The primary goal of this study is to evaluate the effect of a multimodal prehabilitation preoperative program on changes in frailty…
- Conditions
- Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- HOPE (NCT03642093)
- Testing
- Nutritional Intervention, Physical Activity Intervention
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Siobhan Trotter
Image, Body, Cervix Cancer
A Novel Functional Imaging Technique With FLT-PET/MRI For Staging, Response Assessment and Radiation Treatment Planning in Cervix Cancer
This pilot study aims to monitor early tumour response based on [18F]FLT-PET/MRI scans and to determine the feasibility of personalised radiotherapy to spare active bone marrow areas identified by [18F]FLT-PET/MRI.
- Trial name
- NCT05355558
- Testing
- [18F]FLT-PET/MRI body scan
- Where
- Singapore
- Volunteers
- 15 people
- Sponsor
- National Cancer Centre, Singapore
Oral Squamous Cell Carcinoma
Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
The trial is a single-center, non-randomized feasibility study aiming to evaluate the feasibility of ex-vivo tissue analysis using differential mobility spectrometry (DMS) of tissue smoke generated by the use of an…
- Trial name
- NCT05902455
- Testing
- Punch biopsy
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Tampere University Hospital
Esophageal Squamous Cell Carcinoma
A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
This study is aimed to evaluate the efficacy and safety of sintilimab combined with chemotherapy versus chemotherapy in perioperative treatment of locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06152978
- Testing
- Sintilimab, Chemotherapy
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Fudan University
Epithelial Ovarian Cancer, Gastric Adenocarcinoma
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies.
- Conditions
- Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
- Trial name
- MK-2870-001 (NCT04152499)
- Testing
- SKB264
- Where
- 109 sites in United States, Canada and 4 more
- Volunteers
- 1,410 people
- Sponsor
- Klus Pharma Inc.
Endometrial Cancer, Vulvar Cancers
The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Mapping in Gynecological Cancer
This research will determine the impact of optimizing dosage and storage conditions for indocyanine green on health outcomes and will contribute to improving treatment processes in gynecological cancers.
- Conditions
- Endometrial Cancer, Vulvar Cancers, Cervical Cancer, Indocyanine Green (ICG)
- Trial name
- DOSTCONICG (NCT07380698)
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Cukurova University
Neoplasms, Head and Neck
Change in Symptom Clusters in HNC Patients
Head and neck cancer (HNC) is the sixth most common malignancy worldwide, causing more than 379,000 deaths in 2015 notwithstanding the breakthrough in cancer screening and medical treatment.
- Trial name
- NCT03356093
- Testing
- complete questionnaire
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University
Diabetes Mellitus, Sarcoidosis
Salivary Proteins in Disease and Health
This study will examine saliva samples from healthy volunteers and patients with various diseases to learn more about how disease affects the mouth and salivary glands.
- Conditions
- Diabetes Mellitus, Sarcoidosis, Dental Caries, Sjorgren's Syndrome
- Trial name
- NCT00100204
- Where
- United States
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Head and Neck Cancer
S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as S-1 and tegafur-uracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00336947
- Testing
- tegafur-gimeracil-oteracil potassium, tegafur-uracil, adjuvant therapy
- Where
- 48 sites in Japan
- Volunteers
- 500 people
- Sponsor
- Yokohama City University
Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer
Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
70% all cases of cervical cancer, 95% of anal cancers and about 70% of oropharyngeal cancers are linked to Human Papillomavirus (HPV) infection. HPV oncogenic proteins are trans-activators of telomerase.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer, Cervical Cancer
- Trial name
- VolATIL (NCT03946358)
- Testing
- Blood sample collection, Tumor biopsies, CT scan
- Where
- 4 sites in France
- Volunteers
- 47 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Esophageal Cancer, Reflux, Gastroesophageal
Evaluating Acid Reflux After Oesophageal Stenting Using Anti-reflux Stents
Incurable oesophageal cancer remains a global problem and in South Africa the vast majority of patients with oesophageal cancer have advanced disease at first presentation and are not curable.
- Trial name
- NCT05303298
- Testing
- Anti-reflux oesophageal stent, Conventional oesophageal stent
- Where
- South Africa
- Volunteers
- 72 people
- Sponsor
- University of Cape Town
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Squamous Cell Carcinoma of Esophagus
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus
Albumin-bound paclitaxel regimen in advanced NSCLC has a better tumor response rate and safety than solvent-based paclitaxel. However, the safety and efficacy is uncertain in neoadjuvant therapy in esophageal cancer.
- Trial name
- NCT02033538
- Testing
- nanoparticle albumin-bound paclitaxel
- Where
- China
- Sponsor
- Zhejiang University
Advanced Solid Tumors, NSCLC
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have…
- Conditions
- Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC
- Trial name
- NCT04157985
- Testing
- Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Dan Zandberg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.